This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2017 Dec;5(12):e8.

doi: 10.1016/S2213-8587(17)30369-8.

Correction to Lancet Diabetes Endocrinol 2016; 4: 1004-16

No authors listed

PMID: 29173506
DOI: 10.1016/S2213-8587(17)30369-8

Published Erratum

Correction to Lancet Diabetes Endocrinol 2016; 4: 1004-16

No authors listed. Lancet Diabetes Endocrinol. 2017 Dec.

. 2017 Dec;5(12):e8.

doi: 10.1016/S2213-8587(17)30369-8.

PMID: 29173506
DOI: 10.1016/S2213-8587(17)30369-8

No abstract available

PubMed Disclaimer

Erratum for

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA. Frías JP, et al. Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016. doi: 10.1016/S2213-8587(16)30267-4. Epub 2016 Sep 16. Lancet Diabetes Endocrinol. 2016. PMID: 27651331 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations